LivsMed announced that it completed an initial public offering worth approximately $94 million on Korea’s KOSDAQ market.
Seoul-based LivsMed said its offering drew “significant interest” from major domestic pension funds and institutions and large global financial institutions headquartered in New York and Boston.
Related: 4DMedical secures $150M backing from institutional investors
The company says that its debut as a public company led to its market capitalization surpassing approximately $1 billion. It plans to use its proceeds to build an integrated production base, fund R&D and strengthen related management systems to support global growth across its product portfolio.
LivsMed’s product portfolio includes the ArtiSential line of fully articulating handheld laparoscopic instruments. The company designed the platform to provide wrist-like dexterity. It also expanded the platform with ArtiSeal, a 90-degree articulating vessel sealer that enables multi-angle access in confined anatomy.
The company hopes to bring its technology to the U.S. market alongside its Stark surgical robot. In July 2025, it unveiled the Stark system’s telsurgery capabilities in an early feasibility wet lab conducted with Sovato. In the demonstration, a surgeon console was located in Santa Barbara, California, with the robotic system in Chicago.
“As we scale globally, we remain focused on making advanced surgical capability more accessible,” said Jung Joo Lee, founder and CEO of LivsMed. “An innovation cannot be called an innovation unless it can reach the masses.”
